ANIK Q3 2021 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$208M

Q3 2021 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$40M+24.7% YoY

Gross Profit

$23M58.2% margin

Operating Income

$1M3.3% margin

Net Income

$558,0001.4% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

+3.6%

Cash Flow

Operating Cash Flow

$2M

Free Cash Flow

$778,000

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$353M

Total Liabilities

$63M

Stockholders' Equity

$290M

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$40M	$32M	+24.7%
Gross Profit	$23M	$17M	+32.8%
Operating Income	$1M	-$8M	+116.4%
Net Income	$558,000	-$6M	+108.7%

Revenue Segments

Product

$40M50%

Joint Pain Management Therapies

$26M33%

Joint Preservation and Restoration

$11M14%

Manufactured Product, Other

$2M3%

Geographic Segments

UNITED STATES

$31M88%

Europe

$4M12%